New hope for myeloma patients: drug combo shows promise in Transplant-Ineligible
Disease control
Recruiting now
This study tests a new combination of drugs (iberdomide, bortezomib, dexamethasone, and isatuximab) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this treatment can achieve a very deep response (stringent c…
Phase: PHASE2 • Sponsor: Canadian Myeloma Research Group • Aim: Disease control
Last updated May 07, 2026 18:38 UTC